查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493316

製药中心/病患访问支援服务市场规模、份额和趋势分析报告：按服务类型、服务提供类型、区域和细分市场预测：2024-2030

Pharma HUB And Patient Access Support Service Market Size, Share & Trends Analysis Report By Service Type (Program Enrollment, Treatment Navigators), By Service Delivery Type, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

製药中心/病患访问支援服务市场的成长和趋势：

Grand View Research, Inc.最新报告显示，2024年至2030年，全球製药中心和病患准入支援服务市场将以9.9%的复合年增长率成长，到2030年将达到57亿美元。

这一增长是由患有罕见疾病和需要获得特定药物的罕见疾病患者数量显着增加所推动的。此外，强调建立以患者为中心的生态系统并在整个治疗过程中为患者提供良好支持，以及对旨在改善患者治疗效果的客製化解决方案不断增长的需求也推动了市场的发展。

罕见疾病的流行正在推动製药中心和患者获取支援服务市场的成长。背景因素包括对特殊治疗的需求、对罕见疾病药物开发的奖励、由于稀有性而支持患者获取的需要、全球合作体係以及罕见疾病治疗市场的扩大。这些因素导致製药业的投资、创新和合作增加，特别是在罕见疾病研发和病患支援服务相关领域。

欧盟有多达 3,600 万人受到罕见疾病的影响，疾病种类超过 6000 种。有些罕见疾病只影响少数人，而有些则影响多达 245,000 人。这些疾病中约 80% 具有遗传根源，其中 70% 是在儿童时期形成的。此外，超过 10,000 种罕见疾病影响着美国超过 3,000 万人。此外，据估计，印度有 6% 至 8% 的人口受到罕见和超罕见疾病的影响。因此，罕见疾病的显着流行预计将有助于市场成长。

透过创建以患者为中心的生态系统，製药公司将患者的需求放在第一位，并在整个治疗过程中提供支持他们的服务。这是由于影响患者治疗的多种因素造成的，包括缺乏适当的培训、不遵守药物治疗、担心副作用和错过预约。一旦患者接受了特定治疗方法，他们就可以存取相关的患者服务资源并开始与您的组织合作。

先进的分析和人工智慧技术为患者服务团队提供了可行的见解，以随着治疗的进展满足每位患者的个人需求。这种量身定制的方法可确保患者在正确的时间获得正确的支持，从而改善治疗结果。例如，Managed Markets Insight &Technology, LLC、IQVIA 和 IntegriChain 等公司提供此类解决方案来克服患者访问障碍。

此外，生命科学产业正在适应数位时代，重点关注基于价值的护理和优先考虑综合服务的结果主导模型。这种转变导致了整合解决方案中技术进步的采用，从而改善了患者的就诊并改善了医疗保健结果。 TrialCard 的新企业 SaaS PatientLink 平台就是一个例子。 PatientLink 于 2022 年 4 月推出，简化了病患存取和参与病患援助计画的过程，同时提高了用药依从性。这是一种提供全通路体验的高度可配置服务，生命科学领导者可以透过多系统互通性满足苛刻的医疗保健市场的需求。

製药中心/病患访问支援服务市场报告亮点

  • 按服务类型划分，2023年节目註册产业占最大市场占有率。这种增长是由于对客製化解决方案的需求不断增长以及对改善患者治疗效果的需求不断增长而推动的。
  • 依服务提供类型划分，2023年综合服务细分市场占据最大市场占有率。其优势在于，整合解决方案提供了一个统一的平台来管理各种功能，例如病患存取协助、报销协助和药局协调。
  • 2023年，北美在全球市场中占据最大的收益占有率。这一增长归因于糖尿病和心血管疾病等与文明病的增加、基于临床试验的研究的增加、该地区市场参与者的强大存在，并且美国和其他国家有许多已开发国家。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章製药中心/病患访问支援服务市场的变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 製药中心/病患访问支援服务市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19 的影响

第四章 製药中心/病患访问支援服务市场：服务类型估计与趋势分析

  • 2023年及2030年服务类型市场占有率
  • 细分仪表板
  • 全球製药中心/病患访问支援服务市场：按服务类型分類的展望
  • 节目註册
  • 治疗导航器
  • 报销服务/平价服务
  • 临床教育家
  • 专业药房和配药的协调
  • 其他的

第五章 製药中心/病患访问支援服务市场：服务提供类型的估计和趋势分析

  • 2023年及2030年服务提供类型的市场占有率
  • 细分仪表板
  • 全球製药中心和病患访问支援服务市场：按服务交付类型分類的展望
  • 综合服务
  • 独立服务

第六章 製药中心和病人访问支援服务市场：区域估计和趋势分析，按服务类型，按服务提供类型

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第七章 竞争格局

  • 最新趋势与影响分析：主要市场参与企业
  • 公司/竞争对手分类
    • 创新者
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • PharmaCord
    • Fortrea
    • AssistRx
    • CareMetx
    • ConnectiveRx
    • Lash Group
    • McKesson
    • Inizio Engage
    • NS Pharma, Inc. (a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.)
    • Sonexus Health (acquired by Cardinal Health)
    • Envoy Health Management, LLC (independently operated subsidiary of Diplomat Pharmacy, Inc.)
    • EVERSANA
    • United BioSource LLC (UBC)
    • Mercalis
Product Code: GVR-4-68040-278-6

Pharma HUB And Patient Access Support Service Market Growth & Trends:

The global pharma HUB and patient access support service market size is expected to reach USD 5.7 billion by 2030, registering a CAGR of 9.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the significant prevalence of rare and orphan-diseased patients requiring access to specific medicines. Furthermore, the market is driven by an emphasis on establishing a patient-centered ecosystem to provide extensive support to patients throughout their treatment and an increasing demand for tailored solutions aimed at improving patient outcomes.

The prevalence of rare diseases has fueled growth in the pharmaceutical hub and patient access support service market. It is driven by specialized treatment demand, incentives for orphan drug development, the need for patient access support due to rarity, global collaborative efforts, and an expanding market for rare disease treatments. These factors have led to increased investment, innovation, and collaboration in the pharmaceutical industry, particularly in areas related to rare disease research, development, and patient support services.

Up to 36 million people in the EU are affected by rare diseases, which encompass over 6,000 distinct conditions. While some rare diseases impact only a few patients, others can affect as many as 245,000 individuals. About 80% of these diseases have genetic roots, with 70% beginning in childhood. Furthermore, in the U.S., over 10,000 rare diseases impact more than 30 million people. Moreover, it's estimated that 6-8% of the population in India is affected by rare or ultra-rare diseases. Hence, the significant prevalence of rare diseases is expected to contribute to the market growth.

Pharmaceutical companies are prioritizing the needs of patients by creating a patient-centric ecosystem that offers services to support them throughout their therapy journey. This is due to various factors such as lack of proper training, medication non-adherence, and fear of adverse effects, or missed appointments, which can affect a patient's treatment. Patients can access relevant patient service resources and start engaging with the organization as soon as they are prescribed a particular therapy.

With advanced analytics and AI technology, patient services teams can now obtain actionable insights to cater to each patient's individual needs as they progress through their treatment journey. This tailored approach ensures that patients receive the right support at the right time, leading to better therapy outcomes. For instance, companies such as Managed Markets Insight & Technology, LLC, IQVIA, & IntegriChain are offering such solutions in order to overcome barriers to patient access.

Furthermore, the life sciences industry is adapting to the digital era by focusing on value-based care and outcome-driven models that prioritize integrated services. This shift has led to the adoption of technological advancements in integrated solutions to enhance patient access and improve healthcare outcomes. One such example is the PatientLink platform, a new enterprise SaaS by TrialCard. Launched in April 2022, PatientLink simplifies patient access and engagement with Patient Support Programs while improving adherence to medication. It is a highly configurable service that offers an omnichannel experience, enabling leaders in life sciences to meet the needs of a demanding healthcare marketplace through multi-system interoperability.

Pharma HUB And Patient Access Support Service Market Report Highlights:

  • Based on service type, the program enrollment segment held the largest market share in 2023. Its growth can be attributed to growing demand for customized solutions and the increasing need to improve patient outcomes drive
  • Based on service delivery type, the integrated services segment held the largest market share in 2023. Its dominance is because the integrated solutions offer a unified platform to manage various functions such as patient access support, reimbursement assistance, and pharmacy coordination
  • North America dominated the global market with the largest revenue share in 2023. Its growth can be attributed to the rising prevalence of lifestyle-associated diseases, such as diabetes & cardiovascular disorders, growing number of clinical trial-based research, strong presence of market players in the region, and presence of developed countries, such as the U.S.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Service Type
    • 1.1.2. Service Delivery Type
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
    • 1.6.3. Volume price analysis (Model 2)
    • 1.6.4. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Service type outlook
    • 2.2.2. Service delivery type outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Pharma HUB And Patient Access Support Service Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Pharma HUB And Patient Access Support Service Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & legal landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social & environmental landscape
      • 3.3.2.4. Technological landscape
    • 3.3.3. Impact of COVID-19

Chapter 4. Pharma HUB And Patient Access Support Service Market: Service Type Estimates & Trend Analysis

  • 4.1. Service Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Pharma HUB And Patient Access Support Service Market by Service Type Outlook
  • 4.4. Program Enrollment
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.4.2. Order processing
      • 4.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.4.3. Application processing
      • 4.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.4.4. Ease of enrollment (through phone, face, portal, or app)
      • 4.4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.4.5. Program data
      • 4.4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Treatment Navigators
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.2. Process flows and standard operating procedures
      • 4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.3. Program literature and scripts
      • 4.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.4. Care team training
      • 4.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.5. Systems testing and optimization
      • 4.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.6. Reimbursement Services/Affordability Services
    • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.7. Clinical Educator
    • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.8. Coordination of Specialty Pharmacy/Dispensing
    • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Pharma HUB And Patient Access Support Service Market: Service Delivery Type Estimates & Trend Analysis

  • 5.1. Service Delivery Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Pharma HUB And Patient Access Support Service Market by Service Delivery Type Outlook
  • 5.4. Integrated Services
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5. Standalone Services
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Pharma HUB And Patient Access Support Service Market: Regional Estimates & Trend Analysis, By Service Type, By Service Delivery Type

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Denmark
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Norway
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Innovators
    • 7.2.2. List of key distributors and channel partners
    • 7.2.3. Key customers
    • 7.2.4. Key company market share analysis, 2023
    • 7.2.5. PharmaCord
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Fortrea
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. AssistRx
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. CareMetx
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. ConnectiveRx
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Lash Group
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. McKesson
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Inizio Engage
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives
    • 7.2.13. NS Pharma, Inc. (a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.)
      • 7.2.13.1. Company overview
      • 7.2.13.2. Financial performance
      • 7.2.13.3. Product benchmarking
      • 7.2.13.4. Strategic initiatives
    • 7.2.14. Sonexus Health (acquired by Cardinal Health)
      • 7.2.14.1. Company overview
      • 7.2.14.2. Financial performance
      • 7.2.14.3. Product benchmarking
      • 7.2.14.4. Strategic initiatives
    • 7.2.15. Envoy Health Management, LLC (independently operated subsidiary of Diplomat Pharmacy, Inc.)
      • 7.2.15.1. Company overview
      • 7.2.15.2. Financial performance
      • 7.2.15.3. Product benchmarking
      • 7.2.15.4. Strategic initiatives
    • 7.2.16. EVERSANA
      • 7.2.16.1. Company overview
      • 7.2.16.2. Financial performance
      • 7.2.16.3. Product benchmarking
      • 7.2.16.4. Strategic initiatives
    • 7.2.17. United BioSource LLC (UBC)
      • 7.2.17.1. Company overview
      • 7.2.17.2. Financial performance
      • 7.2.17.3. Product benchmarking
      • 7.2.17.4. Strategic initiatives
    • 7.2.18. Mercalis
      • 7.2.18.1. Company overview
      • 7.2.18.2. Financial performance
      • 7.2.18.3. Product benchmarking
      • 7.2.18.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 4 North America pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 5 U.S. pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 6 U.S. pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 7 Canada pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 8 Canada pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 9 Europe pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 11 Europe pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 12 Germany pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 13 Germany pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 14 UK pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 15 UK pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 16 France pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 17 France pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 18 Italy pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 19 Italy pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 20 Spain pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 21 Spain pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 22 Denmark pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 23 Denmark pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 24 Sweden pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 25 Sweden pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 26 Norway pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 27 Norway pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 31 China pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 32 China pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 33 Japan pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 34 Japan pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 35 India pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 36 South Korea pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 37 South Korea pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 38 Australia pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 39 Australia pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 40 Thailand pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 41 Thailand pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 42 Latin America pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
  • Table 43 Latin America pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 44 Latin America pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 45 Brazil pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 46 Brazil pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 47 Mexico pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 48 Mexico pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 49 Argentina pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 50 Argentina pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 51 MEA pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
  • Table 52 MEA pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 53 MEA pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 54 South Africa pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 55 South Africa pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 58 UAE pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 59 UAE pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 60 Kuwait pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 61 Kuwait pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Pharma HUB and patient access support service market: market outlook
  • Fig. 9 Credentialing software and services competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Pharma HUB and patient access support service market driver impact
  • Fig. 15 Pharma HUB and patient access support service market restraint impact
  • Fig. 16 Pharma HUB and patient access support service market strategic initiatives analysis
  • Fig. 17 Pharma HUB and patient access support service market: Service type movement analysis
  • Fig. 18 Pharma HUB and patient access support service market: Service type outlook and key takeaways
  • Fig. 19 Program enrollment market estimates and forecast, 2018 - 2030
  • Fig. 20 Order processing market estimates and forecast, 2018 - 2030
  • Fig. 21 Application processing market estimates and forecast, 2018 - 2030
  • Fig. 22 Ease of enrollment (through phone, face, portal, or app) market estimates and forecast, 2018 - 2030
  • Fig. 23 Program data market estimates and forecast, 2018 - 2030
  • Fig. 24 Treatment navigators market estimates and forecast, 2018 - 2030
  • Fig. 25 Process flows and standard operating procedures market estimates and forecast, 2018 - 2030
  • Fig. 26 Program literature and scripts market estimates and forecast, 2018 - 2030
  • Fig. 27 Care team training market estimates and forecast, 2018 - 2030
  • Fig. 28 Systems testing and optimization market estimates and forecast, 2018 - 2030
  • Fig. 29 Reimbursement services/affordability services market estimates and forecast, 2018 - 2030
  • Fig. 30 Clinical educator market estimates and forecast, 2018 - 2030
  • Fig. 31 Coordination of specialty pharmacy/dispensing market estimates and forecast, 2018 - 2030
  • Fig. 32 Others market estimates and forecast, 2018 - 2030
  • Fig. 33 Pharma HUB and patient access support service market: Service delivery type movement analysis
  • Fig. 34 Pharma HUB and patient access support service market: Service delivery type outlook and key takeaways
  • Fig. 35 Integrated services market estimates and forecast, 2018 - 2030
  • Fig. 36 Standalone services market estimates and forecast, 2018 - 2030
  • Fig. 37 Pharma HUB and patient access support service market: Regional movement analysis
  • Fig. 38 Pharma HUB and patient access support service market: Regional outlook and key takeaways
  • Fig. 39 Pharma HUB and patient access support service market share and leading players
  • Fig. 40 North America market share and leading players
  • Fig. 41 Europe market share and leading players
  • Fig. 42 Asia Pacific market share and leading players
  • Fig. 43 Latin America market share and leading players
  • Fig. 44 Middle East & Africa market share and leading players
  • Fig. 45 North America: SWOT
  • Fig. 46 Europe SWOT
  • Fig. 47 Asia Pacific SWOT
  • Fig. 48 Latin America SWOT
  • Fig. 49 MEA SWOT
  • Fig. 50 North America, by country
  • Fig. 51 North America
  • Fig. 52 North America market estimates and forecasts, 2018 - 2030
  • Fig. 53 U.S.
  • Fig. 54 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 55 Canada
  • Fig. 56 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 57 Europe
  • Fig. 58 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 59 UK
  • Fig. 60 UK market estimates and forecasts, 2018 - 2030
  • Fig. 61 Germany
  • Fig. 62 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 63 France
  • Fig. 64 France market estimates and forecasts, 2018 - 2030
  • Fig. 65 Italy
  • Fig. 66 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 67 Spain
  • Fig. 68 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 69 Denmark
  • Fig. 70 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 71 Sweden
  • Fig. 72 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 73 Norway
  • Fig. 74 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 75 Asia Pacific
  • Fig. 76 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 77 China
  • Fig. 78 China market estimates and forecasts, 2018 - 2030
  • Fig. 79 Japan
  • Fig. 80 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 81 India
  • Fig. 82 India market estimates and forecasts, 2018 - 2030
  • Fig. 83 Thailand
  • Fig. 84 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 85 South Korea
  • Fig. 86 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 87 Australia
  • Fig. 88 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 89 Latin America
  • Fig. 90 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 91 Brazil
  • Fig. 92 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 93 Mexico
  • Fig. 94 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 95 Argentina
  • Fig. 96 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 97 Middle East and Africa
  • Fig. 98 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 99 South Africa
  • Fig. 100 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 101 Saudi Arabia
  • Fig. 102 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 103 UAE
  • Fig. 104 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 105 Kuwait
  • Fig. 106 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 107 Market share of key market players- Pharma HUB and patient access support service market